How to buy CurveBeam AI (CVB) Shares
Firms are refining methods to produce images of the body’s insides and help medical specialists diagnose issues such as frail bones.
Want to start buying CVB shares but not sure how? Follow the steps below to invest in CurveBeam AI on the ASX.
1. Find a stock trading platform
To buy shares listed in Australia, you'll need to sign up with an investment platform that has access to the ASX. There are a number of share trading platforms in Australia, of which Stake is one.
2. Fund your account
Complete an application with your personal and financial details. Fund your investment account with a bank transfer, debit card or even Apple/Google pay.
3. Search for CurveBeam AI ($CVB)
Find the share by company name or ticker symbol: $CVB. Do your own research to ensure it is the right investment product for your own circumstances. Consider seeking financial, legal and taxation advice before investing.
4. Choose an order type and buy CVB stock
Buy on any trading day with a market order or use a limit order to delay your purchase of CVB shares until it reaches your desired stock price. Look into dollar cost averaging to consider spreading out your risk, which smooths out buying at consistent intervals.
5. Monitor your investment
Optimise your portfolio by tracking how your stock and the business perform. You may be eligible for dividends and shareholder voting rights that affect your stock.
CurveBeam AI overview
CurveBeam AI ($CVB) aims to further the development of its medical testing technology with funds from a recent ASX listing.
The firm develops, manufacturers and sells a range of specialised medical imaging scanners. These are commonly known as computerised tomography (CT) scanners, which are a diagnostic technology to produce images of the inside of the body.
CurveBeam also offers supporting software with their products to help aid medical practitioners with clinical assessments. Their product suite uses some AI and deep learning technologies to help identify whether patients have frail bones. They expect to expand on this segment in the future.
They aim to help with the diagnosis and management of musculoskeletal conditions such as osteoporosis and osteoarthritis. These issues are more common in the elderly and those who’ve received joint replacements. If undiagnosed and untreated these ailments can lead to fractures, chronic pain, disability, and reduced quality of life.
CurveBeam’s devices have received regulatory clearance for sales in several jurisdictions including the U.S, Germany, and Australia. However, further steps are needed to meet all licensing approvals before all their software products can be launched to existing clients.
Their main customers are orthopaedic surgeon groups, chains offering imaging services and hospitals. CurveBeam has an agreement with medical technology firm, Stryker Corporation ($SYK), to promote and distribute their products in the U.S.
The IPO has provided new funds to help grow the business, but there are still many tasks ahead before CurveBeam’s team could fully realise the value of their products. Future revenues depend on the full approval of its AI software and acceptance of their devices by the medical community.
CurveBeam AI (CVB) IPO details
CurveBeam AI has filed its prospectus with the Australian Securities and Investments Commission (ASIC) in order to be listed on the ASX using the ticker symbol CVB. Read more in the CurveBeam AI prospectus.
Total number of shares available under the offer
Funds raised for IPO
ASX listing date
You can take a look at the top shareholders in CVB in this document.
If you're considering investing in the CurveBeam AI listing or other upcoming IPOs, sign up today.
This does not constitute financial advice nor a recommendation to invest in the securities listed. The information presented is intended to be of a factual nature only. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing.
Megan is a markets analyst at Stake, with 7 years of experience in the world of investing and a Master’s degree in Business and Economics from The University of Sydney Business School. Megan has extensive knowledge of the UK markets, working as an analyst at ARCH Emerging Markets - a UK investment advisory platform focused on private equity. Previously she also worked as an analyst at Australian robo advisor Stockspot, where she researched ASX listed equities and helped construct the company's portfolios.